S. M. Domchek

800 citations

21 papers · 400 indexed · h-index 8

Co-authors: M. William Audeh Mark E. Robson Judy E. Garber Andrew Tutt J. Carmichael Michael Friedländer Jeffrey N. Weitzel Bella Kaufman
Topics: BRCA gene mutations in cancer (11 papers)PARP inhibition in cancer therapy (10 papers)Advanced Breast Cancer Therapies (7 papers)
Cited by: Oncology Reproductive Medicine Cancer Research
Journals: Journal of Clinical Oncology Cancer Research Annals of Oncology
Partner nations: United States United Kingdom France

In The Last Decade

S. M. Domchek

21 papers receiving 386 citations

Peers

Countries citing papers authored by S. M. Domchek

Since Specialization

Citations

This map shows the geographic impact of S. M. Domchek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. M. Domchek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. M. Domchek more than expected).

Fields of papers citing papers by S. M. Domchek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. M. Domchek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. M. Domchek. The network helps show where S. M. Domchek may publish in the future.

Co-authorship network of co-authors of S. M. Domchek

This figure shows the co-authorship network connecting the top 25 collaborators of S. M. Domchek. A scholar is included among the top collaborators of S. M. Domchek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. M. Domchek. S. M. Domchek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations 2025 ·Annals of Oncology ·Clare Turnbull,Maria Isabel Achatz,Judith Balmañà,(unknown),Giuseppe Curigliano,Cezary Cybulski,S. M. Domchek,D. Gareth Evans,Helen Hanson,Nicoline Hoogerbrugge,Paul A. James,Andreas Krause,Katherine L. Nathanson,Joanne Ngeow,Mark E. Robson,Marc Tischkowitz,C. Benedikt Westphalen,William D. Foulkes	4
2	Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) 2019 ·Cancer Research ·S. M. Domchek,Sophie Postel‐Vinay,S-A. Im,Winnie Yeo,J.P. Delord,Antoîne Italiano,Jérôme Alexandre,Benoît You,Susan E.P. Bastian,(unknown),Saiama N. Waqar,Mark C. Lanasa,(unknown),Minhong Tang,Christopher Gresty,(unknown),Pia Herbolsheimer,Bella Kaufman	16
3	Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts 2019 ·Cancer Research ·S. M. Domchek,Sophie Postel‐Vinay,S-A. Im,Y.H. Park,J.P. Delord,Antoîne Italiano,Jérôme Alexandre,Benoît You,Susan E.P. Bastian,(unknown),Saiama N. Waqar,Mark C. Lanasa,(unknown),Minhong Tang,Christopher Gresty,(unknown),Pia Herbolsheimer,Bella Kaufman	6
4	Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC) 2018 ·Cancer Research ·S. M. Domchek,Sophie Postel‐Vinay,Y-J. Bang,YH Park,Jérôme Alexandre,J.P. Delord,Antoîne Italiano,Benoît You,Susan E.P. Bastian,Matthew Krebs,Dawei Wang,Saiama N. Waqar,Helen K. Angell,Maria Learoyd,Shan‐Chwen Chang,Christopher Gresty,Pia Herbolsheimer,Bella Kaufman	41
5	Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 2018 ·Cancer Research ·S. M. Domchek,Mark E. Robson,S-A. Im,Elżbieta Senkus,Binghe Xu,Norikazu Masuda,Suzette Delaloge,(unknown),Anne Armstrong,Pierfranco Conté,Wendy Bannister,Carsten Goessl,Sarah Runswick,Sanjay Goel,Nadine Tung	3
6	Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 2018 ·European Journal of Cancer ·Elżbieta Senkus,S. M. Domchek,Seock‐Ah Im,Binghe Xu,Anne Armstrong,Norikazu Masuda,(unknown),(unknown),Nadine Tung,Pierfranco Conté,Wencheng Wu,Carsten Goessl,Sarah Runswick,Mark E. Robson	10
7	OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC) 2017 ·Annals of Oncology ·Mark E. Robson,Kathryn J. Ruddy,S-A. Im,Elżbieta Senkus,Binghe Xu,S. M. Domchek,Norikazu Masuda,Suzette Delaloge,W. Li,Nadine Tung,Anne Armstrong,Weiwen Wu,Carsten Goessl,Arnold Degboe,Pierfranco Conté	4
8	Abstract P4-22-14: Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer 2017 ·Cancer Research ·(unknown),X Wang,Andrea B. Troxel,(unknown),Michael D. Feldman,Priti Lal,Panpan Zhang,Mark Rosen,Maryann Gallagher,(unknown),(unknown),Jennifer M. Matro,S. M. Domchek,Kenneth R Fox,Peter J. O’Dwyer,Angela DeMichele	5
9	Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety 2016 ·Annals of Oncology ·Ursula A. Matulonis,Richard T. Penson,S. M. Domchek,Bella Kaufman,Ronnie Shapira‐Frommer,M. William Audeh,S.B. Kaye,L. Rhoda Molife,Karen A. Gelmon,Jane Robertson,Helen Mann,Tony W. Ho,Robert L. Coleman	125
10	Abstract P2-16-20: Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer 2013 ·Cancer Research ·(unknown),Priti Lal,(unknown),(unknown),Michael D. Feldman,(unknown),Maryann Gallagher,S. M. Domchek,Keerthi Gogineni,Stephen J. O’Keefe,Kenneth R Fox,Peter J. O’Dwyer,Angela DeMichele	3
11	Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? 2011 ·Journal of Clinical Oncology ·S. M. Domchek,Tara M. Friebel,Susan L. Neuhausen,Henry T. Lynch,CF Singer,Rosalind A. Eeles,Claudine Isaacs,(unknown),PA Ganz,(unknown),Jeffrey N. Weitzel,(unknown),Wendy S. Rubinstein,Gail E. Tomlinson,(unknown),(unknown),Ellen Matloff,D. Gareth Evans,J. E. Garber,Timothy R. Rebbeck	16
12	Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). 2010 ·Journal of Clinical Oncology ·Andrew J. Rech,Rosemarie Mick,(unknown),A. DeMichele,(unknown),Kevin R. Fox,S. M. Domchek,Robert H. Vonderheide	6
13	Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. 2009 ·Cancer Research ·Lori J. Pierce,Kelly‐Anne Phillips,Kent A. Griffith,Saundra S. Buys,David K. Gaffney,(unknown),(unknown),Merav Ben‐David,Judy E. Garber,Sofía D. Merajver,(unknown),Amichay Meirovitz,S. M. Domchek	3
14	Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer 2009 ·Journal of Clinical Oncology ·Andrew Tutt,Mark E. Robson,Judy E. Garber,S. M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedländer,J. Carmichael	98
15	Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer 2009 ·Journal of Clinical Oncology ·Andrew Tutt,Mark E. Robson,Judy E. Garber,S. M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedländer,J. Carmichael	18
16	Genetic counseling for BRCA1 and BRCA2 mutations in African American women. 2009 ·Cancer Research ·(unknown),Lisa Kessler,(unknown),(unknown),S. M. Domchek	1
17	Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer 2009 ·Journal of Clinical Oncology ·Robert H. Vonderheide,Patricia LoRusso,(unknown),Elisabeth I. Heath,Depinder Khaira,(unknown),Prudence Dorazio,G Mariani,Tiziana Usari,S. M. Domchek	3
18	Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer 2008 ·Journal of Clinical Oncology ·L.J. Pierce,Kathleen A. Griffith,Saundra Buys,David K. Gaffney,(unknown),(unknown),Merav Ben‐David,J. E. Garber,Sofía D. Merajver,Amichay Meirovitz,S. M. Domchek	2
19	Utilization of oncotype DX in node-negative, ER-positive breast cancer patients 2007 ·Journal of Clinical Oncology ·(unknown),(unknown),(unknown),(unknown),A. DeMichele,Kenneth R Fox,S. M. Domchek	2
20	Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer 2005 ·Annals of Oncology ·Jennifer E. Schwartz,S. M. Domchek,Wei‐Ting Hwang,Kenneth R Fox	31

About S. M. Domchek

S. M. Domchek is a scholar working on Oncology, Genetics and Cancer Research, having authored 21 papers that have together received 400 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (10 papers) and Advanced Breast Cancer Therapies (7 papers). The work is most often cited by research in Oncology (317 citations), Reproductive Medicine (80 citations) and Cancer Research (98 citations). S. M. Domchek has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include M. William Audeh, Mark E. Robson, Judy E. Garber, Andrew Tutt, J. Carmichael, Michael Friedländer, Jeffrey N. Weitzel, Bella Kaufman, Helen Mann and Richard T. Penson. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact